CG Oncology, Inc.

NasdaqGS:CGON Stock Report

Market Cap: US$4.2b

CG Oncology Management

Management criteria checks 2/4

CG Oncology's CEO is Arthur Kuan, appointed in Jan 2017, has a tenure of 9.08 years. total yearly compensation is $11.17M, comprised of 5.8% salary and 94.2% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth $1.88M. The average tenure of the management team and the board of directors is 2.5 years and 3.4 years respectively.

Key information

Arthur Kuan

Chief executive officer

US$11.2m

Total compensation

CEO salary percentage5.85%
CEO tenure9.1yrs
CEO ownership0.04%
Management average tenure2.5yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene

Jan 11

We're Not Very Worried About CG Oncology's (NASDAQ:CGON) Cash Burn Rate

Jul 16
We're Not Very Worried About CG Oncology's (NASDAQ:CGON) Cash Burn Rate

A First Take On CG Oncology

Jan 10

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Dec 13

Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth

Oct 04
Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth

CG Oncology: Promising Data, But Looks Expensive

Aug 26

CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate

Jul 25
CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 09

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 06

CEO Compensation Analysis

How has Arthur Kuan's remuneration changed compared to CG Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$151m

Jun 30 2025n/an/a

-US$128m

Mar 31 2025n/an/a

-US$106m

Dec 31 2024US$11mUS$653k

-US$88m

Sep 30 2024n/an/a

-US$79m

Mar 31 2024n/an/a

-US$72m

Dec 31 2023US$4mUS$449k

-US$68m

Sep 30 2023n/an/a

-US$57m

Dec 31 2022US$1mUS$394k

-US$44m

Compensation vs Market: Arthur's total compensation ($USD11.17M) is above average for companies of similar size in the US market ($USD6.81M).

Compensation vs Earnings: Arthur's compensation has increased whilst the company is unprofitable.

CEO

Arthur Kuan (34 yo)

9.1yrs
Tenure
US$11,172,793
Compensation

Mr. Arthur Kuan serves as Chief Executive Officer and Director at CG Oncology, Inc. since 2017 and also serves as Chairman since December 2023. Mr. Kuan served as the Chief Operating Officer of CG Oncology...

Leadership Team

NamePositionTenureCompensationOwnership
Arthur Kuan
Chairman & CEO9.1yrsUS$11.17m0.045%
$ 1.9m
Ambaw Bellete
President & COO2.6yrsUS$5.24m0%
$ 0
James DeTore
Interim Principal Financial & Accounting Officerless than a yearno datano data
Swapnil Bhargava
Chief Technical Officer2.4yrsno datano data
Amy Steele
Vice President of Finance & Administration4.1yrsno datano data
Joshua Patterson
General Counsel1.8yrsno datano data
Sarah Connors
Vice President of Communications & Patient Advocacyno datano datano data
Bing Kung
Vice President of Corporate Developmentno datano datano data
Vijay Kasturi
Chief Medical Officer2.5yrsUS$2.44m0.0016%
$ 68.4k
2.5yrs
Average Tenure
54yo
Average Age

Experienced Management: CGON's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Arthur Kuan
Chairman & CEO9.1yrsUS$11.17m0.045%
$ 1.9m
Leonard Post
Lead Independent Director7.3yrsUS$475.57kno data
Victor Tong
Independent Director2.6yrsUS$444.30k0%
$ 0
James Mule
Independent Director7.3yrsUS$437.16k0%
$ 0
Susan Graf
Independent Director2.3yrsUS$455.90k0%
$ 0
Brian Liu
Independent Director3.4yrsUS$447.58k0%
$ 0
Christina Rossi
Directorless than a yearno datano data
3.4yrs
Average Tenure
50.5yo
Average Age

Experienced Board: CGON's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/02 14:16
End of Day Share Price 2026/02/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CG Oncology, Inc. is covered by 18 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Chen YangBofA Global Research
Joshua SchimmerCantor Fitzgerald & Co.